There are more and more agents to consider for hidradenitis suppurativa (HS). Thus, choices can now be made based on the individual needs of the patient . A few questions need to be answered when treating HS patients with biologics: who should receive them, what drug to choose, and how to switch drugs in case of treatment failure?
“How does your HS impact you?” This is an essential question that Prof. Joslyn Kirby (Penn State University, USA) asks her patients before deciding about treatment, since objective severity should not be the only determining variable. Factors that can influence objective severity include flare frequency and scarring. Scarring is usually observed in Hurley stages II or III with tunnels but can also be seen in patients without tunnels; in these cases, biologics may be an additional option. Indeed, the patient has to be willing to take a biologic and might need some education about the disease, as many of them still believe in th...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Cannabinoids: a future role in dermatology? Next Article
HS patients carry higher risk for systemic lupus erythematosus »
Table of Contents: AAD 2020
Psoriasis – What Is Hot?
Systemic Therapies for Dermatologists
Hidradenitis Suppurativa/Acne Inversa
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.